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TImaging  has  become  an  essential  aspect  of  several  levels  of
cancer  management.  To  begin  with,  it  fulﬁls  ever  more  proﬁ-
ciently  its  classic  tasks  of  early  diagnosis  of  primary  tumours,
staging,  evaluation  of  treatment  efﬁcacy  and  detection  of
recurrence.  Secondly,  and  it  has  been  doing  this  for  a  long
time  now,  it  can  be  used  for  intervention  methods  provid-
ing  palliative  care  (draining,  embolisation,  etc.),  to  relieve
suffering  or  prolong  the  life  of  patients  with  incurable  can-
cers.  For  about  ﬁfteen  years  it  has  also  been  ’invading’  the
domain  of  curative  treatment,  by  precisely  guiding  meth-
ods  of  tumour  destruction,  methods  that  are  less  and  less
invasive  and  in  which  the  radiologist  plays  a  prominent
role.
The  aim  of  this  CME  book  is  to  take  stock  of  recent
advances  in  morphological,  functional  and  therapeutic  imag-
ing  in  uro-oncology.
The  front  lines,  however,  are  not  the  same  in  each  case,
but  depend  on  the  particular  organ.
Progress  has  perhaps  been  most  marked  in  kidney  cancer,
where  histological  classiﬁcation  is  changing,  as  E.  Compérat
and  P.  Camparo  describe,  to  become  morphological  and
cytogenetic.  It  is  the  radiologist’s  duty  to  follow  these  devel-
opments,  because  we  no  longer  ask  him  just  to  detect
renal  masses,  but  also  to  characterise  them,  and  to  do
so  as  precisely  as  possible.  In  a  very  informative  paper,
O.  Hélénon  et  al.,  recall  just  how  far  modern  imaging  can
go  in  characterising  small  solid  renal  masses,  and  pro-
pose  a  practical  classiﬁcation  system  which  could  become
the  equivalent  of  Bosniak’s  classiﬁcation  system  for  cys-
tic  masses.  Finally,  the  team  in  Bordeaux  review  the  renal
tumour  destruction  methods  that  are  rapidly  developing
and  now  offer  a  credible  alternative  to  partial  nephrec-
tomy.
The  situation  is  considerably  different  for  cancer  of  the
prostate,  which  has  been  resisting  imaging  for  such  a  long
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doi:10.1016/j.diii.2012.04.004ime that  we  still  rely  on  random  biopsies  to  detect  it.  But
ts  defences  are  gradually  giving  way,  particularly  due  to
he  progress  in  multiparametric  MRI.  It  is  true  that  the  lat-
er  still  needs  to  be  standardised  and  reﬁned,  but  a  time
an  be  envisaged  when  it  will  provide  precise  maps  of  the
osition  of  tumour  foci  and  post-therapeutic  recurrences,
nd  the  chances  are  that  it  is  going  to  become  increas-
ngly  part  of  our  daily  practice.  The  teams  in  Lille  and  Lyon
ive  details  in  this  issue  of  the  state  of  the  art  regard-
ng  multiparametric  MRI  and  dare  to  ask  the  sacrilegious
uestion,  ‘‘Will  we  one  day  be  able  to  do  without  random
iopsies?’’
For  urothelial  cancers,  the  best  management  results
rom  good  use  of  imaging,  endoscopy  and  urinary  cytol-
gy,  respectively,  as  M.  Roupret  reminds  us.  There  are  still
ossibilities  for  improvement,  however,  particularly  in  pari-
tal  and  local  staging  of  tumours  of  the  bladder.  C.  Roy
xplains  the  advances  of  MRI  in  this  area,  as  yet  inadequately
xplored.
Finally,  this  issue  ends  with  two  papers  on  cancers
f  the  external  male  genital  organs.  For  testicular  can-
er,  a  model  of  the  success  of  modern  oncology—with
ecovery  rates  of  99%  for  the  early  stages  and  90%  for
ertain  metastatic  forms—the  battle  is  almost  won.  Even
f  there  are  still  points  to  be  improved  (particularly  eval-
ation  of  the  viability  of  residual  lymph  node  masses
fter  chemotherapy),  we  are  already  at  the  stage  of
eing  able  to  envisage  a  reduction  in  monitoring  by  CT,
n  order  to  reduce  the  irradiation  of  patients!  The  situa-
ion  is  completely  different  for  cancer  of  the  penis,  for
hich  mutilating  treatment  remains  the  only  possibility.
he  most  important  role  of  imaging,  still  poorly  known
n  this  area,  is  to  ensure  precise  local  staging  so  that,
henever  possible,  the  treatment  preserves  as  much  as
ossible.
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We  hope  that  this  wide-ranging  overview  will  provide  all
ur  readers  with  an  accurate  idea  of  the  state  of  the  art  and
ermit  them  to  make  use  of  some  of  these  advances  in  their
aily  practice.
In  the  meantime  we  must  wait  for  the  front  lines  to  move
orward  again. .  .Continuing  education  program:  Editorial
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